Similarly, an anti-MIC-A/B mAb that blocks NKG2D ligand shedding from tumor cells potentiated NK cell-mediated tumor rejection in a CD16- and NKG2D-dependent manner in a preclinical model [176]. Here, KLRK1 is linked to neoplasm.